Which of the statements about the 2025 American College of Rheumatology guideline for the treatment of systemic lupus ...

Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug ...

J&J's phase IIb JASMINE study on nipocalimab meets key endpoints in systemic lupus erythematosus, supporting plans to advance ...

Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...

Imaavy will now progress to Phase III in SLE, though it will face strong competition from SLE market leader, Benlysta, if ...

Higher levels of antimitochondrial antibodies in patients with systemic lupus erythematosus are tied to a higher risk for ...

Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US ...

Low baseline 25 (OH)D levels are associated with higher mortality and cardiovascular event risks among patients with systemic lupus erythematosus (SLE), with evidence of a U-shaped relationship ...

Johnson & Johnson (JNJ) stock is in focus as the company's experimental therapy for systemic lupus erythematosus hits the ...

The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...

Johnson & Johnson said it will initiate a Phase 3 trial of its treatment for systemic lupus erythematosus, or SLE, after a recent study of the therapy met its primary endpoint.

In today’s ACT Brief, we examine why representative enrollment remains a barrier in US cancer trials, review Johnson & ...